Table I.
Characteristics of the Study Group (n = 172).
| Characteristics | Category | n (%) |
|---|---|---|
| Age (years) | Median [range] | 32 [16–81] |
| ≥60 | 20 (12) | |
| Response to frontline therapy | CR | 140 (81) |
| No CR | 32 (19) | |
| Duration of first CR (months) | 0 | 32 (18) |
| 1–11 | 63 (37) | |
| 12–36 | 43 (25) | |
| Karyotype | Diploid | 64 (37) |
| Philadelphia-positive | 27 (16) | |
| Other | 44 (26) | |
| Insufficient metaphases/not done | 30 (17)/7 (4) | |
| Hemoglobin (g/dL) | Median [range] | 11 [6–36.6] |
| <10 | 49 (29) | |
| WBC (× 109/L) | Median [range] | 5.4 [0.2–292.5] |
| ≥5 | 93 (55) | |
| Platelets (× 109/L) | Median [range] | 104 [8–418] |
| <25 | 19 (11) | |
| 25–100 | 63 (37) | |
| >100 | 88 (52) | |
| Albumin (g/L) | Median | 3.8 [1.7–4.9] |
| <3.8 | 75 (46) | |
| Year of study | 1990–2000 | 104 (60) |
| 2001–2007 | 68 (40) | |
| Marrow blast % | Median [range] | 58 [0–99] |
| 20–50 | 29 (17) | |
| >50 | 91 (54) | |
| Peripheral blast % | Median [range] | 1 [0–98] |
| 1 | 4 (2) | |
| >1 | 82 (49) | |
| LDH (IU/L) | Median [range] | 672 [180–15 779] |
| >672 | 86 (50) |
CR, complete response; WBC, white blood cell count; LDH, lactate dehydrogenase.